Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study to assess real-world patterns of chemotherapy utilization among patients with metastatic gastric and esophageal adenocarcinoma with use of ramucirumab plus paclitaxel

Next Previous
Trial Profile

A retrospective study to assess real-world patterns of chemotherapy utilization among patients with metastatic gastric and esophageal adenocarcinoma with use of ramucirumab plus paclitaxel

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Intestinal cancer; Oesophageal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 13 May 2021 Primary endpoint (OS which is defined as time from cancer diagnosis till death of any reason.) has been met according to Results published in the American Journal of Clinical Oncology
  • 13 May 2021 New trial record
  • 01 Apr 2021 Results published in the American Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top